PET/CT in renal and bladder cancers

Archive of Oncology

关键词: Kidney Neoplasms;    Urinary Bladder Neoplasms;    Diagnostic Imaging;    Positron-Emission Tomography;    Positron-Emission Tomography and Computed Tomography;    Fluorodeoxyglucose F18;   

DOI  :  10.2298/AOO1204097B

来源: DOAJ

【 摘 要 】

FDG is the most frequently used positron emission tomography probe but it hascertain limitations when used in urological cancers due to its urinaryelimination, which prevents the proper visualization of the bladder andkidneys. The introduction of co-registered PET and computed tomography(PET/CT) represents a major advance in technology and now become the newstandard for many cancers. For the staging and surveillance of renal cellcancer, FDG PET/ CT had results that were at least as good as conventionalmethods, which are potentially harmful for the remained renal function.FDG-PET/CT is able to evaluate early response to sunitinib or sorafenibtreatment in metastatic renal cell cancer. An early decrease in the meanglucose uptake was found in both soft and skeletal lesions after treatment,thus PET seems to be more advantageous compared with RECIST evaluation. Inaddition, the survival of patients with advanced renal cell cancer can bepredicted by evaluating their SUVmax using FDG-PET/CT. Although urinarybladder cancer demonstrates sufficiently increased FDG uptake, primary tumorsare difficult to identify due to the renal excretion of FDG. The accuracy ofFDG-PET/CT in metabolically active metastases is generally higher whencompared to conventional CT except for identifying small lung deposits.PET/CT with delayed images after a diuretic and oral hydration may improvedetection of locally recurrent or residual UBC and could replace standard CTand bone scintigraphy in the presurgical staging and monitoring of patientswith urinary bladder cancer. 18F-choline PET may be useful for staging ofurinary bladder cancer in addition to FDG PET.

【 授权许可】

Unknown